Samsung Biologics will supply GSK’s innovative biopharmaceutical therapies under an agreement worth more than $231 million over eight years, according to a joint statement. The first commercial supply of belimumab, a human monoclonal antibody that inhibits B-cell activating factor, is expected in 2022 and additional specialty-care products can be expanded in the future.
Samsung Biologics will provide GSK with additional capacity for large-scale biopharmaceutical product manufacturing, and the capacity will be flexible depending on GSK’s future needs and will supplement GSK's existing manufacturing network, the statement said.
"We are very proud and excited to announce this long-term agreement with GSK," Samsung Biologics CEO Kim Tae-han was quoted as saying.
"Today’s agreement with Samsung Biologics complements and reinforces our existing world-class pharmaceutical manufacturing capability and will help ensure we can continue to deliver the transformative medicines that patients need," said Regis Simard, president of GSK's pharmaceuticals supply chain.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.